The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2022
Filed:
Nov. 16, 2020
Applicant:
The University of British Columbia, Vancouver, CA;
Inventors:
Yuzhuo Wang, Vancouver, CA;
Stephen Yiu Chuen Choi, Vancouver, CA;
Assignee:
The University of British Columbia, Vancouver, CA;
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 31/7088 (2006.01); C07H 21/04 (2006.01); A61K 31/713 (2006.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/337 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61P 35/00 (2018.01); C07H 21/04 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/341 (2013.01); C12N 2320/31 (2013.01);
Abstract
Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC).